If you have a compelling family history of ovarian cancer that is not explained by a mutation in the BRCA1 or BRCA2 gene, it is possible that a mutation in the RAD51D gene could be the explanation.
More on the Woman Who Filed an EEOC Complaint Claiming She Was Fired Over a Genetic Test Revealing a BRCA2 Mutation
The internet is abuzz with all kinds of information related to the case that we discussed yesterday here inovolving a Connecticut woman, Pamela Fink, who has filed a complaint with the EEOC and others alleging genetic discrimination under GINA (Genetic Information Nondiscrimination Act) . She states that her former employer, MXenergy, fired her because of a genetic test that revealed that she carried a mutation in the BRCA2 gene, which confers very high lifetime risks of breast and ovarian cancer.
Video is beginning to emerge (thanks to Nature News for pointing us in this direction) with more information about the case.
The Yale Cancer Genetic Counseling blog notes that on April 1, Myriad reportedly raised the full price for full sequencing and rearrangement testing of the BRCA1 and BRCA2 genes to $4,040 (from $3,770).
Woman Files Complaint Claiming She Was Fired Over Positive BRCA2 Test for Hereditary Breast and Ovarian Cancer
In one of the first complaints filed related to the Genetic Insurance Nondiscrimination Act, a Connecticut woman has filed complaints with the U.S. Equal Opportunity Commission and the Connecticut Commission on Human Rights and Opportunities. According to the Boston Herald, Pamela Fink, 39, of Fairfield, Connecticut, alleges that her employer, MXenergy fired her after she disclosed to them that she had a mutation in the BRCA2 gene (which confers hereditary breast and ovarian cancer susceptibility).
Daily Beast Writer, Lizzie Stark’s perspective on her prophylactic mastectomy for a BRCA mutation, “Good-Bye to My Breasts”
If you have a compelling family history of breast and ovarian cancer that is not explained by a mutation in the BRCA1 or BRCA2 gene, it is possible that the RAD51C gene could be the explanation. An international research team demonstrated that mutations in RAD51C can lead to hereditary breast and ovarian cancer risk in a paper published online in Nature Genetics yesterday.
The invalidation of Myriad Genetics’ patents related to testing of the BRCA1 and BRCA2 genes is no laughing matter for those on either side of the issue. Nevertheless, Stephen Colbert’s take on this is worth a look!
Breast Cancer Gene Patenting Lawsuit Pitting ACLU, ACMG and Others Against Myriad Genetics and University of Utah Research Foundation Will Continue
A judge refused to throw out the lawsuit which could plausibly have broad implications for gene patenting…but seems more likely to me to be posturing to encourage a political/legislative solution. Ars Technica has excellent coverage here.
Two papers published online today in the journal Nature (abstracts available here and here) show us why this is the case at least in a subset of cases in individuals with BRCA2 mutations.